Fight COVID-19 with BioTechPharma

Point-of-Care Device

Press

Researchers at George Mason Developing Quicker Coronavirus Antibody Test

Watch Video
  • NBC Washington

Mason researchers developing saliva test for COVID-19 antibodies

Read more
  • GMU News

About Us

Summary

Established in 1994, BIOTECHPHARMA provides innovative point-of-care testing devices, laboratory services, mobile lab staffing with program management, and pharmaceutical manufacturing.

Markets Served:

  • Nursing Homes
  • Employment Screening
  • Hospitals & Rehab Centers
  • Federal Agencies
  • Law Enforcement
  • DOT Regulated Employers

: Example Patents :

8,940,527

Integrated Sample Collection & Testing with Confirm & ID

7,741,103

Integrated Sample Collection with I.D.

7,879,623

Integrated Sample Collection with I.D.

6,352,863

Nanotechnology Platform

Feature Technology

COVID-19 IgG/IgM Rapid Test Device

BioTechPharma Corp (BTP) has developed a Point-of-Care COVID-19 diagnostic device. The COVID-19 (aka SARS-CoV-2, 2019-nCoV, or coronavirus) antibodies, IgG and IgM, have been detected accurately by BTP COVID-19 IgG/IgM Rapid Test Device. Two separate clinical trials on 470 patients produced accuracy between 98.6%-99.1%. The BTP COVID-19 Rapid Test Device kits are dramatically different than current laboratory-based DNA Analysis methods to determine the presence of the coronavirus. BTP focused on the antibody detection using proprietary test strips made by Lateral Flow Testing (https://lftstrip.com/) .

BTP then housed the proprietary test strips in lateral flow devices that are accurate, rapid, portable, and easy to administer. BTP COVID-19 Rapid Test Device delivers results in 10 minutes at point-of-care. For FDA Emergency Use Authorization status, See: FDA EUA COVID-19 List

Get to Know Us

The BioTechPharma Team

Dr. Raouf Guirguis

Chairman and Chief Executive Officer

Dr. Guirguis is a serial inventor and entrepreneur who has had numerous medical inventions commercialized including Saliva-based nanotechnology (colloidal gold) vertical-flow test strips for Point-of-Care testing. His technologies have been used by corporation including DuPont, Bristol-Myers, Squibb, MonoGen, Cytyc, Hologic, Point of Care Fingerprint Biotech, Syva, Dade Behring, Siemens and mLife DX

Dr. Lance Liotta

Lab Consultant and Scientific Advisor

Co-Director and Co-founder of the Center for Applied Proteomics and Molecular Medicine at George Mason University. Past Roles: Former Chief of the Laboratory of Pathology, National Cancer Institute; Deputy Director of National Institute of Health; and Co-Director of the NCA/FDA Clinical Proteomics Program. Dr. Liotta’s research has been cited tens of thousands of times and he is a coveted speaker and researcher.